^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
BGB-B167
i
Other names: BGB-B167
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
BeiGene
Drug class:
CD137 agonist, CEACAM5 inhibitor
Related drugs:
11ms
Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=55, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting | Phase classification: P1a/1b --> P1 | N=254 --> 55 | Trial completion date: Aug 2025 --> Jan 2025
Enrollment closed • Phase classification • Enrollment change • Trial completion date • Combination therapy • Metastases
|
Tevimbra (tislelizumab-jsgr) • BGB-B167
12ms
Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants (clinicaltrials.gov)
P1, N=0, Withdrawn, BeiGene | Phase classification: P1a/1b --> P1 | N=254 --> 0 | Not yet recruiting --> Withdrawn
Phase classification • Enrollment change • Trial withdrawal
|
Tevimbra (tislelizumab-jsgr) • BGB-B167
1year
Safety, Pharmacokinetics and Antitumor Activity of BGB-B167alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants (clinicaltrials.gov)
P1a/1b, N=254, Not yet recruiting, BeiGene | Initiation date: Sep 2023 --> Mar 2024
Trial initiation date • Combination therapy • Metastases
|
Tevimbra (tislelizumab-jsgr) • BGB-B167
over1year
Safety, Pharmacokinetics and Antitumor Activity of BGB-B167alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants (clinicaltrials.gov)
P1a/1b, N=254, Not yet recruiting, BeiGene | Initiation date: May 2023 --> Sep 2023
Trial initiation date • Combination therapy • Metastases
|
Tevimbra (tislelizumab-jsgr) • BGB-B167
Share via
